Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01607905 · ClinicalTrials.gov registry record · Phase 1
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
A Phase 1 study, sponsored by Karyopharm Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 192
- Enrollment target
NCT01607905 is a Phase 1 study that has completed, run by Karyopharm Therapeutics. The registered enrollment target is 192 participants.
The verdict
NCT01607905, a Phase 1 study, has completed, sponsored by Karyopharm Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 192 participants
- Enrollment target
Study Summary
Phase 1 study to evaluate the safety and tolerability of selinexor and determine the Recommended Phase 2 Dose (RP2D) of selinexor for advanced or metastatic solid tumor malignancies.
Interventions
- DRUG Acetaminophen
- DRUG Selinexor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2012-06-18 |
| Est. Completion | 2016-03-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01607905
The ClinicalTrials.gov registry entry for NCT01607905 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Karyopharm Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Acetaminophen is the first listed.
NCT01607905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01607905 about?
NCT01607905 is a clinical study titled "Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer". Phase 1 study to evaluate the safety and tolerability of selinexor and determine the Recommended Phase 2 Dose (RP2D) of selinexor for advanced or metastatic solid tumor malignancies.
What is the current status of trial NCT01607905?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 192 participants. The study started on 2012-06-18. Estimated completion is 2016-03-15.
What interventions are being tested in trial NCT01607905?
The interventions under investigation include: Acetaminophen (DRUG), Selinexor (DRUG).
Who is sponsoring clinical trial NCT01607905?
This trial is sponsored by Karyopharm Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.